Publisher
Springer International Publishing
Reference29 articles.
1. Chabner B, Wilson W, Supko J. Pharmacology and toxicity of antineoplastic drugs. In:Williams haematology. 7th ed. New York: McGraw-Hill; 2006. p. 249–74.
2. Fernandez H. New trends in the standard of care for initial therapy. Hematology Am Soc Hematol Educ Program. 2010;2010:56–61.
3. Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149(2):244–9.
4. Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85(2):130–8.
5. Almeida AM, Pierdomenico F. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: effective management with concomitant prednisolone. Leuk Res. 2012;36(9):e211–3.